CanSino Biologics’ Quadrivalent Meningococcal Conjugate Vaccine Age Extension Application Accepted by the National Medical Products Administration
December 2, 2024
Source: drugdu
29
According to CanSino's official WeChat account, the supplemental application for CanSino Biologics' ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 carrier), referred to as "Mankexin®," has been accepted by the National Medical Products Administration (NMPA) and a notice of acceptance has been issued. This supplemental application expands the age range for the use of Mankexin® from "3 months to 3 years (47 months) children" to "3 months to 6 years (83 months) children." Mankexin® received approval from the NMPA on December 29, 2021.
https://finance.eastmoney.com/a/202411263251192857.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- AstraZeneca, who will replace Wang Lei? December 2, 2024
- The first nasal “dry eye” treatment drug is approved for marketing December 2, 2024
- CAR-T, a special medicine for tumors, is out of the medical insurance again December 2, 2024
- 400 million antibacterial injections, Huiyu Pharmaceutical has won the first imitation! November 30, 2024
- China Resources Pharmaceutical Commercial and Pfizer officially sign a strategic cooperation agreement November 30, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
